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vone; 9.0 mg / kg, n  5) or saline (control group; n 
5) at the same time as removing the clamps. Five hours
after de-clamping, the muscles of lower extremity were
harvested. Tissues were stained with hematoxylin &
eosin (HE), in order to count the viable muscle cells.
They were also stained with periodic acid-Schiff (PAS),
in order to assess the glycogen storage in muscle cells.
Results: The density of viable muscle cells in the
group edaravone was significantly greater than that of
control group (59360 cells/mm2 vs. 25831 cells/
mm2, P  .01). The mean percentage of PAS-positive
area in the edaravone group was also significantly higher
than that in control group (30.1  6.9 % vs. 7.3  2.1%,
P  .001, Fig, original 200x).
Conclusions: Our results suggest that edaravone in-
jected at the start of reperfusion can also reduce muscle
injury following leg ischemia in rats, storing a high level
of glycogen in viable muscle cells. Therefore, edaravone
might be useful in clinical settings following leg isch-
emia.
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Objectives: The nephroprotective effect of ascorbic
acid in humans receiving intravenous contrast in percu-
taneous coronary interventions is beginning to be estab-
lished. Currently there is no data from either clinical or
in vivo models assessing the potential of ascorbic acid as
a nephroprotective agent in patients undergoing Endo-
vascular Aneurysm Repair.
We used an in vivo murine model to evaluate the
potential therapeutic effect and appropriate dosage of
vitamin C to prevent contrast induced nephropathy
(CIN).
Methods: A total of 24 mice were divided into 4
groups, mice from all groups (except the negative con-
trol) received Omnipaque and were then treated with;
low or high dose ascorbic acid or saline positive and
negative controls. Urine was collected and pooled from
each group before and after the various treatments then
centrifuged and analysed for NGAL (neutrophil gelatine
associated lipoprotein). At the end of the study kidneys
from each mouse were explanted and frozen. One kidney
per mouse was analysed by histopathology and immuno-
histochemical staining for haematoxylin-eosin (HE),
caspase-3, NGAL and TUNEL (transferase mediated
dUTP nick-end labelling). The remaining kidney was
lysed and analysed for expression of NGAL by ELISA.
Results: Kidney lysate NGAL ELISA analysis dem-
onstrated a 50% reduction in renal damage in animals
receiving low dose following contrast administration,
although this degree of protection was not observed in
the high dose group. There was no significant difference
in the degree of renal injury seen between groups by HE
staining, however initial immunohistochemistry for
markers of early apoptosis showed a decrease in caspase 3
expression in both low and high dose ascorbic acid
groups compared to the positive control.
Conclusions: Our mouse model suggests that one
mechanism for acute renal injury induced by contrast media
may involve caspase-dependent apoptosis, and that ascorbic
acid administration can prevent CIN. Further work is sug-
gested in human subjects on this topic.
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